Download the full report (112 p.) - KCE

90 Interventions in Alzheimer’s Disease KCE Reports 111
8 REFERENCES
1. NICE-SCIE. Dementia: supporting people with dementia and their carers in health and social
care. Care guideline. National Institute for Health and Clinical Excellence (NICE) and Social
Care Institute for Excellence; 2006. Clinical Guideline 42 Available from:
2.
http://www.nice.org.uk/guidance/cg42
Kurz X, Scuvee-Moreau J, Salmon E, Pepin JL, Ventura M, Dresse A, et al. [Dementia in
Belgium: prevalence in aged patients consulting in general practice]. Rev Med Liege.
2001;56(12):835-9.
3. Qualidem. Reports of Qualidem I and II projects. 2005. Available from: www.qualidem.be
4. Mitchell A, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia -
meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009.
5. Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG, Old Age Task Force of the World
Federation of Biological P. Systematic review of psychological approaches to the management
of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162(11):1996-2021.
6. Folstein M, Folstein S, McHugh P. Mini-Mental State: A practical method for grading the
cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12:189-98.
7. Hasselbalch SG, Baloyannis S, Denislic M, Dubois B, Oertel W, Rossor M, et al. Education and
training of European neurologists in dementia. Eur J Neurol. 2007;14(5):505-9.
8. De Lepeleire J, Ylieff M, Buntinx F, Bouckaert F, Steeman E, Van Tichelt K, editors. Omgaan
met dementerenden. Aanbevelingen van het Qualidem-project. : Garant; 2007.
9. RIZIV/INAMI. Het doelmatig gebruik van geneesmiddelen bij de behandeling van dementie bij
ouderen. Consensus vergadering 24 november 2005. Folia Pharmacotherapeutica 2006;33(7).
10. BCFI. Transparantiefiche. Geneesmiddelen bij Dementie. 2008. Available from:
11.
http://www.bcfi.be/pdf/tft/TN_DEM.pdf
Wind A, Gussekloo J, Vernooij-Dassen M. NHG-Standaard Dementie (tweede herziening).
Huisarts Wet 2003;46(13):754-67.
12. Nederlandse Vereniging voor Klinische Geriatrie. Richtlijn. Diagnostiek en medicamenteuze
behandeling van dementie. 2005.
13. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, et al. Recommendations
for the diagnosis and management of Alzheimer's disease and other disorders associated with
dementia: EFNS guideline. Eur J Neurol. 2007;14(1):e1-26.
14. SBU. Dementia – Diagnostic and Therapeutic Interventions. A systematic review. Volume 2.
June 2008. SBU; 2008. Available from: www.sbu.se
15. Duara R, Loewenstein DA, Potter E, Appel J, Greig MT, Urs R, et al. Medial temporal lobe
atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology. 2008;71(24):1986-92.
16. Nordberg A. Amyloid imaging in Alzheimer's disease. Curr Opin Neurol. 2007;20(4):398-402.
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (IV-
TR), 4th edn-text revised Washington DC.; 2000.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of
Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of
Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology.
1984;34(7):939-44.
19. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Memantin bei Alzheimer
Demenz. Vorbericht A05-19C. Köln: IQWiG; 2008. Available from:
20.
http://www.iqwig.de/download/A05-19C_Vorbericht_Memantin_bei_Alzheimer_Demenz.pdf
Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al.
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA
criteria. Lancet Neurol. 2007;6(8):734-46.
21. SBU. Dementia – Caring, Ethics, Ethnical and Economical Aspects. A systematic review.
Volume 3. June 2008. SBU; 2008. Available from: www.sbu.se
22. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test
battery for use in Alzheimer disease clinical trials. Arch Neurol. 2007;64(9):1323-9.